NYSE American accepts Serina plan to regain listing compliance by July 2027

Reuters04-03
NYSE American accepts Serina plan to regain listing compliance by July 2027
  • NYSE American accepted Serina Therapeutics’ plan to regain compliance with continued listing standards.
  • Cure period runs through July 9, 2027, with shares remaining listed during that time subject to other standards.
  • Company received a noncompliance notice on Jan. 9, 2026 tied to stockholders’ equity of $1.6 million.
  • NYSE American will monitor progress quarterly, with suspension and delisting procedures possible if targets are not met by deadline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604021613PRIMZONEFULLFEED9683733) on April 02, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment